45
Participants
Start Date
January 18, 2017
Primary Completion Date
September 19, 2018
Study Completion Date
March 18, 2022
Ustekinumab
Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
Universitair Kinderziekenhuis Koningin Fabiola, Brussels
UZ Brussel, Jette
Cliniques Universitaires Saint Luc, Brussels
UZ Leuven, Leuven
UZ Gent, Ghent
Mount Sinai, New York
Childrens Hospital Of Philadelphia, Philadelphia
Center For Digestive Health Systems-Greenville, Greenville
Emory University, Atlanta
Children's Center For Digestive Healthcare, Llc, Atlanta
HELIOS Klinikum Wuppertal GmbH, Wuppertal
Mayo Clinic, Rochester
Methodist Medical Center of Illinois, Peoria
Hôpital Necker, Paris
Hôpital Robert Debré, Paris
Dr. von Haunersches Kinderspital, Munich
Cedars Sinai Medical Center, Los Angeles
Connecticut Childrens Medical Center, Hartford
Stollery Children's Hospital, Edmonton
British Columbia Children's Hospital, Vancouver
Children's Hospital of Western Ontario, London
Hospital For Sick Children, Toronto
Centre Hospitalier Sainte Justine, Montreal
Instytut Centrum Zdrowia Matki Polki, Lodz
WIP Warsaw IBD Point Profesor Kierkus, Warsaw
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw
Janssen Research & Development, LLC
INDUSTRY